CXC chemokines: the regulatory link between inflammation and angiogenesis.

Abstract Chemokines are multifunctional mediators mainly responsible for leukocyte recruitment to inflamed tissues. Cytokines of the CXC family, however, also have a pivotal role in the control of inflammation and angiogenesis, as a result of the shared expression of their specific receptors by leukocytes and endothelial cells. Although the mechanisms of activity of angiogenic chemokines are known, the identification of those responsible for CXC chemokine-mediated angiostatic effects has been difficult. The recent discovery of a novel variant of CXCR3 (CXCR3-B) as a common receptor for all four angiostatic chemokines (CXCL4, CXCL9, CXCL10 and CXCL11) has enabled a better understanding of how CXC chemokines not only influence the sequential participation of inflammatory cells but also regulate, in a coordinate way, the inflammatory reaction leading to angiogenesis, tissue repair and new tissue generation. Dysregulation of this fine regulatory network can lead to abnormalities, such as chronic inflammation, dysplastic transformation and even tumor development and spreading. Thus, targeting of these chemokines or their receptors might provide a successful therapeutic approach in chronic inflammatory and neoplastic diseases.

[1]  A. Wells,et al.  Glu-Leu-Arg-negative CXC chemokine interferon gamma inducible protein-9 as a mediator of epidermal-dermal communication during wound repair. , 2003, The Journal of investigative dermatology.

[2]  D. Markovitz,et al.  Interleukin-8 and Growth-Regulated Oncogene Alpha Mediate Angiogenesis in Kaposi's Sarcoma , 2002, Journal of Virology.

[3]  R. Strieter,et al.  CXC chemokines in angiogenesis related to pulmonary fibrosis. , 2002, Chest.

[4]  E Lazzeri,et al.  Interferon-inducible protein 10, monokine induced by interferon gamma, and interferon-inducible T-cell alpha chemoattractant are produced by thymic epithelial cells and attract T-cell receptor (TCR) alphabeta+ CD8+ single-positive T cells, TCRgammadelta+ T cells, and natural killer-type cells in hum , 2001, Blood.

[5]  A. Wells,et al.  Ip-10 Inhibits Epidermal Growth Factor–Induced Motility by Decreasing Epidermal Growth Factor Receptor–Mediated Calpain Activity , 1999, The Journal of cell biology.

[6]  M. Iannettoni,et al.  Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. , 1998, The Journal of clinical investigation.

[7]  M. Burdick,et al.  Enhanced tumor‐forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth‐regulated cytokine β and γ proteins , 1997 .

[8]  D. Kolson,et al.  CXCR3 expression in human central nervous system diseases , 2001, Neuropathology and applied neurobiology.

[9]  S. Nishikawa,et al.  Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 , 1996, Nature.

[10]  P. Libby,et al.  Differential Expression of the IFN-γ-Inducible CXCR3-Binding Chemokines, IFN-Inducible Protein 10, Monokine Induced by IFN, and IFN-Inducible T Cell α Chemoattractant in Human Cardiac Allografts: Association with Cardiac Allograft Vasculopathy and Acute Rejection1 , 2002, The Journal of Immunology.

[11]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[12]  M. Volin,et al.  Chemokine receptor CXCR4 expression in endothelium. , 1998, Biochemical and biophysical research communications.

[13]  P. Allavena,et al.  Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.

[14]  G Bernardini,et al.  The chemokine CXCL13 (BCA-1) inhibits FGF-2 effects on endothelial cells. , 2001, Biochemical and biophysical research communications.

[15]  S. Narula,et al.  Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor. , 2001, Cytokine.

[16]  J. Sedgwick,et al.  Tumor Necrosis Factor–dependent Segmental Control of MIG Expression by High Endothelial Venules in Inflamed Lymph Nodes Regulates Monocyte Recruitment , 2001, The Journal of experimental medicine.

[17]  G. Gray,et al.  Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. , 1991, Cancer research.

[18]  L. Luistro,et al.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.

[19]  M. Serio,et al.  Signal Transduction by the Chemokine Receptor CXCR3 , 2001, The Journal of Biological Chemistry.

[20]  E. Rofstad,et al.  Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. , 2000, Cancer research.

[21]  M. Goebeler,et al.  Chemokines in cutaneous wound healing , 2001, Journal of leukocyte biology.

[22]  A. Griffioen,et al.  Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. , 2000, Pharmacological reviews.

[23]  R. Salcedo,et al.  Role of Chemokines in Angiogenesis: CXCL12/SDF‐1 and CXCR4 Interaction, a Key Regulator of Endothelial Cell Responses , 2003, Microcirculation.

[24]  P. Leder,et al.  The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation , 1995, The Journal of experimental medicine.

[25]  J. Norgauer,et al.  Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells. , 1996, Journal of immunology.

[26]  Claudio Ronco,et al.  Blood and dialysate flow distributions in hollow-fiber hemodialyzers analyzed by computerized helical scanning technique. , 2002, Journal of the American Society of Nephrology : JASN.

[27]  H. Nomiyama,et al.  Chemokines in immunity. , 2001, Advances in immunology.

[28]  J. Finke,et al.  The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. , 1998, Journal of immunology.

[29]  D. Ribatti,et al.  Analysis of the role of chemokines in angiogenesis. , 2003, Journal of immunological methods.

[30]  A. Zlotnik,et al.  The biology of chemokines and their receptors. , 2000, Annual review of immunology.

[31]  R. Schreiber,et al.  Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. , 1994, Journal of immunology.

[32]  Simon A. Jones,et al.  Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes , 1996, The Journal of experimental medicine.

[33]  I. Katz,et al.  Platelet Factor 4: Production, Structure, and Physiologic and Immunologic Action , 1991, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[34]  Erwin G. Van Meir,et al.  Upregulation of Interleukin 8 by Oxygen-deprived Cells in Glioblastoma Suggests a Role in Leukocyte Activation, Chemotaxis, and Angiogenesis , 1997, The Journal of experimental medicine.

[35]  A. Zlotnik,et al.  Chemokines: a new classification system and their role in immunity. , 2000, Immunity.

[36]  J. Teruya-Feldstein,et al.  Contribution of the CXC chemokines IP‐10 and Mig to the antitumor effects of IL‐12 , 1998, Journal of leukocyte biology.

[37]  P. Wen,et al.  Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth , 1997, Nature Medicine.

[38]  K. Takeda,et al.  Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. , 1996, Journal of immunology.

[39]  A. Bikfalvi,et al.  Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. , 1999, Blood.

[40]  C. Caux,et al.  Antitumor Effects of the Mouse Chemokine 6Ckine/SLC Through Angiostatic and Immunological Mechanisms1 , 2000, The Journal of Immunology.

[41]  G. Gentilini,et al.  Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1). , 1999, Blood.

[42]  A. Richmond,et al.  Delayed wound healing in CXCR2 knockout mice. , 2000, The Journal of investigative dermatology.

[43]  M. Bryckaert,et al.  Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway. , 2002, Blood.

[44]  K. Fung,et al.  Expression Pattern of CXCR3, CXCR4, and CCR3 Chemokine Receptors in the Developing Human Brain , 2001, Journal of neuropathology and experimental neurology.

[45]  M. Sticherling,et al.  Bioactive interleukin-8 is expressed in wounds and enhances wound healing. , 2000, The Journal of surgical research.

[46]  M. Serio,et al.  Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. , 2001, The Journal of clinical investigation.

[47]  S. Werner,et al.  Regulation of wound healing by growth factors and cytokines. , 2003, Physiological reviews.

[48]  J. Teruya-Feldstein,et al.  Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo , 1997 .

[49]  G. Neufeld,et al.  Platelet Factor-4 Inhibits the Mitogenic Activity of VEGF121 and VEGF165 Using Several Concurrent Mechanisms (*) , 1995, The Journal of Biological Chemistry.

[50]  H. Kleinman,et al.  Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. , 1999, The American journal of pathology.

[51]  E. Hudson,et al.  Differential expression and responsiveness of chemokine receptors (CXCR1–3) by human microvascular endothelial cells and umbilical vein endothelial cells , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  T. Yue,et al.  Interferon-inducible Protein-10 Involves Vascular Smooth Muscle Cell Migration, Proliferation, and Inflammatory Response* , 1996, The Journal of Biological Chemistry.

[53]  F. C. Lucibello,et al.  Cell cycle regulation of the cyclin A, cdc25C and cdc2 genes is based on a common mechanism of transcriptional repression. , 1995, The EMBO journal.

[54]  Kouji Matsushima,et al.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.

[55]  B. Evers,et al.  Inflammation and the development of pancreatic cancer. , 2002, Surgical oncology.

[56]  D. Tatakis Human platelet factor 4 is a direct inhibitor of human osteoblast-like osteosarcoma cell growth. , 1992, Biochemical and biophysical research communications.

[57]  Sergio Romagnani,et al.  An Alternatively Spliced Variant of CXCR3 Mediates the Inhibition of Endothelial Cell Growth Induced by IP-10, Mig, and I-TAC, and Acts as Functional Receptor for Platelet Factor 4 , 2003, The Journal of experimental medicine.

[58]  P. Hansell,et al.  Selective binding of platelet factor 4 to regions of active angiogenesis in vivo. , 1995, The American journal of physiology.

[59]  H. Moch,et al.  Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL , 2003, Nature.

[60]  P. Leder,et al.  IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo , 1993, The Journal of experimental medicine.

[61]  A. Zlotnik,et al.  Chemokines: agents for the immunotherapy of cancer? , 2002, Nature Reviews Immunology.

[62]  H. Augustin,et al.  Endothelial cells differentially express functional CXC-chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine activity and exogenous cytokines. , 1998, Biochemical and biophysical research communications.

[63]  A. Angiolillo,et al.  Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. , 1996, Blood.

[64]  M. Salvadori,et al.  Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. , 1999, Journal of the American Society of Nephrology : JASN.

[65]  L. Adorini,et al.  Cutting Edge: Selective Usage of Chemokine Receptors by Plasmacytoid Dendritic Cells1 , 2001, The Journal of Immunology.

[66]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[67]  J. Isner,et al.  Stromal Cell–Derived Factor-1 Effects on Ex Vivo Expanded Endothelial Progenitor Cell Recruitment for Ischemic Neovascularization , 2003, Circulation.

[68]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[69]  M. Parmentier,et al.  Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. , 2001, Blood.

[70]  R. Gamelli,et al.  Modulation of macrophage recruitment into wounds by monocyte chemoattractant protein‐1 , 2001, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[71]  T. Springer,et al.  The Chemokine SDF-1 Is a Chemoattractant for Human CD34+ Hematopoietic Progenitor Cells and Provides a New Mechanism to Explain the Mobilization of CD34+ Progenitors to Peripheral Blood , 1997, The Journal of experimental medicine.

[72]  M. Huising,et al.  Molecular evolution of CXC chemokines: extant CXC chemokines originate from the CNS. , 2003, Trends in immunology.

[73]  T. Springer,et al.  Expression of Stromal-Derived Factor-1 Is Decreased by IL-1 and TNF and in Dermal Wound Healing1 , 2001, The Journal of Immunology.

[74]  J. Teruya-Feldstein,et al.  Contribution of Natural Killer Cells to Inhibition of Angiogenesis by Interleukin-12 , 1999 .

[75]  C. Caux,et al.  Chemokines in cancer. , 2002, Cytokine & growth factor reviews.

[76]  Franklin Peale,et al.  Identification of an angiogenic mitogen selective for endocrine gland endothelium , 2001, Nature.

[77]  D. Remick,et al.  Interleukin‐8 levels and activity in delayed‐healing human thermal wounds , 2000, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[78]  L. Kemény,et al.  Role of interleukin-8 receptor in skin. , 1994, International archives of allergy and immunology.

[79]  E. Bröcker,et al.  Chemokines IL-8, GROalpha, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. , 1998, The American journal of pathology.

[80]  R. Derynck,et al.  Effects of MGSA/GRO alpha on melanocyte transformation. , 1991, Oncogene.

[81]  M. Burdick,et al.  The CXC Chemokine Receptor 2, CXCR2, Is the Putative Receptor for ELR+ CXC Chemokine-Induced Angiogenic Activity1 , 2000, The Journal of Immunology.

[82]  M. Shuman,et al.  Thrombin generation and secretion of platelet Factor 4 during blood clotting. , 1978, The Journal of clinical investigation.